跳至主要内容
临床试验/NCT03913338
NCT03913338已完成不适用

A Controlled Evaluation of the Safety and Efficacy of Laser In-situ Keratomileusis With Crosslinking (XtraLASIK) Compared to Conventional LASIK (convLASIK) in Patients With High Myopia

University Clinic Frankfurt2 个研究点 分布在 1 个国家目标入组 26 人开始时间: 2014年7月24日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
26
试验地点
2
主要终点
best spectacle corrected distant visual acuity

研究概览

简要总结

The objectives of this study are to evaluate the safety and efficacy of a treatment regimen for high myopia and myopic astigmatism: LASIK followed by crosslinking performed with the KXL Crosslinking-System and VibeX Xtra (Riboflavin Ophthalmic Solution, Avedro, USA), as compared to LASIK alone, with regards to regression of refractive outcome, as measured by manifest refraction spherical equivalent (MRSE) and keratometry.

详细描述

This is a controlled study of the safety and efficacy of the KXL System and VibeX Xtra (Riboflavin Ophthalmic Solution, Avedro, USA) for performing crosslinking in eyes undergoing LASIK for high myopia or myopic astigmatism. Each subject will have bilateral LASIK performed and one eye will be randomized to undergo LASIK followed by crosslinking.

Subjects will undergo bilateral LASIK. Following randomisation one eye of each subject will be treated with VibeX Xtra (Riboflavin Ophthalmic Solution) following LASIK and will be irradiated with the KXL System at 30 mW/cm2 intensity for 90 seconds continuous UV-A light treatment for a total radiant exposure of 2.7 J /cm2.

All eyes will be assessed at 1 day, 1, 3, 6, and 12 months after treatment.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • eligible for bilateral myopic fs-LASIK with -6.00 to -12.00 D (diopters) with a maximum of 5.00 D astigmatism
  • age > 18 years
  • provided written informed consent
  • difference between the MRSE and cycloplegic SE less than 0.75 D
  • MRSE needed to be stable for the last 12 months (<0.5 D).

排除标准

  • prior corneal surgery,
  • forme fruste or manifest keratoconus,
  • history of corneal scarring, melting, ulceration
  • repeating inflammations of the eye
  • taking vitamin C 1 week prior to the treatment

研究组 & 干预措施

Study group

Other

LASIK followed by intraoperative application of riboflavin under the flap and crosslinking after reposition of the flap.

干预措施: LasikXtra (Procedure)

Control group

Other

LASIK only

干预措施: LASIK (Procedure)

结局指标

主要结局

best spectacle corrected distant visual acuity

时间窗: 12 months postoperative

best spectacle corrected distant visual acuity (logarithmic minimum angle of resolution)

uncorrected distant visual acuity

时间窗: 12 months postoperative

uncorrected distant visual acuity (logarithmic minimum angle of resolution)

spherical equivalent

时间窗: 12 months postoperative

spherical equivalent (diopter)

次要结局

  • Corneal thickness(12 months postoperative)
  • endothelial cell count(12 months postoperative)
  • Subjective visual quality(12 months postoperative)

研究者

发起方
University Clinic Frankfurt
申办方类型
Other
责任方
Principal Investigator
主要研究者

Professor Dr. med. Thomas Kohnen

Head of Ophthalmology, Principal Investigator, Clinical Professor

University Clinic Frankfurt

研究点 (2)

Loading locations...

相似试验